VMI
BOLD

VHCP Management II’s Audentes Therapeutics, Inc BOLD Stock Holding History

VHCP Management II’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-458,882
Closed -$7.82M – 23
2017
Q1 		$7.82M Hold
458,882
– – 3.2% 7
2016
Q4 		$8.25M Hold
458,882
– – 3.96% 6
2016
Q3 		$7.27M Buy
+458,882
New +$6.96M 3.73% 7

Other funds holding BOLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

VHCP Management II's BOLD Position: Q2 2017 in Review

VHCP Management II sold out of Audentes Therapeutics, Inc (BOLD) in Q2 2017, closing a stake of 458,882 shares — an estimated $7.82M sold.

VHCP Management II first reported a position in BOLD in Q3 2016 and held it in 3 quarters. The position peaked at $8.25M in Q4 2016. 70 funds tracked by Wall St. Rank hold BOLD as of Q2 2017.

  • VHCP Management II reported no remaining Audentes Therapeutics, Inc position as of Q2 2017 after selling out during the quarter.
  • VHCP Management II sold 458,882 Audentes Therapeutics, Inc shares in Q2 2017, an estimated $7.82M.
  • VHCP Management II first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 3 quarters.
  • VHCP Management II's Audentes Therapeutics, Inc position peaked at $8.25M in Q4 2016.
  • 70 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2017.

Based on VHCP Management II's 13F filing for Q2 2017, filed 11 Aug 2017.